Migraine Therapeutics

On this page

Migraine Pathophysiology & Overview - Brain's Ache Saga

  • Definition: Episodic headache disorder; with or without aura (transient focal neurological symptoms).
  • Neurovascular Theory: Primary neuronal dysfunction triggers secondary vascular changes.
  • Cortical Spreading Depression (CSD): Self-propagating wave of neuronal/glial depolarization; underlies migraine aura.
    • Activates trigeminal nerve afferents.
  • Trigeminovascular System Activation: Central to pain.
  • Key Mediators:
    • CGRP (Calcitonin Gene-Related Peptide): Potent vasodilator; neurogenic inflammation.
    • Serotonin (5-HT): Imbalance; 5-HT1B/1D/1F receptor agonism is a key therapeutic target.
    • Substance P, Neurokinin A.

⭐ Activation of the trigeminovascular system releases CGRP, a key player in migraine pain.

Migraine pathophysiology: cortical spreading depression

Acute Migraine Treatment - Attack Abort!

  • Care Approaches:
    • Stratified: Match initial treatment to attack severity.
    • Step-care: Start with simple analgesics, escalate if no response.

    ⭐ Stratified care is often preferred for faster relief and improved outcomes in moderate to severe attacks.

  • Non-Specific Analgesics (Limit use to <15 days/month to avoid MOH):
    • NSAIDs: Ibuprofen, Naproxen, Diclofenac, Aspirin.
    • Paracetamol.
  • Antiemetics (Adjunctive for N/V; some have intrinsic anti-migraine effects):
    • Metoclopramide, Domperidone, Prochlorperazine.
  • Migraine-Specific Agents (Limit use to <10 days/month to avoid MOH):
    • Triptans (5-HT1B/1D Agonists → vasoconstriction, ↓CGRP release):
      • E.g., Sumatriptan, Rizatriptan, Zolmitriptan, Naratriptan, Eletriptan.
      • ADRs: 'Triptan sensations' (chest tightness), flushing.
      • CIs: CAD, stroke/TIA, uncontrolled HTN, hemiplegic/basilar migraine.
      • 📌 Mnemonic: 'A TRIP to the ANus constricts vessels' (vasoconstriction).
    • Ergot Alkaloids (Non-selective 5-HT1, $\alpha$-adrenergic, dopaminergic):
      • Ergotamine, Dihydroergotamine (DHE).
      • ADRs: N/V, ergotism.
      • CIs: CAD, PVD, HTN, pregnancy, potent CYP3A4 inhibitors.
    • CGRP Antagonists (Gepants) (Small molecule CGRP receptor antagonists):
      • Ubrogepant, Rimegepant.
      • Advantages: No vasoconstriction.
    • 5-HT1F Receptor Agonists (Ditans) (Selective 5-HT1F agonist):
      • Lasmiditan.
      • Advantages: No vasoconstriction; useful if triptans CI due to CV risk.
      • ADRs: Dizziness (driving impairment warning).
  • Medication Overuse Headache (MOH):
    • Prevention: Limit acute meds (simple analgesics <15 days/month; triptans/ergots/combo <10 days/month).

Preventive Migraine Treatment - Shield Up Strategies

Indications: ≥4 headache days/month, ≥2 with disability, debilitating attacks, or acute med issues.

  • Oral Prophylactics (selected by comorbidity/ADR profile):
    • Beta-blockers: Propranolol, Metoprolol. MOA: ?Modulate adrenergic/serotonergic systems. ADRs: Fatigue, bradycardia, hypotension. CIs: Asthma, heart block.
    • Antidepressants: Amitriptyline (TCA). MOA: NE & 5-HT reuptake inhibition. ADRs: Sedation, anticholinergic, weight gain. Venlafaxine (SNRI) alternative.
    • Anticonvulsants:
      • Topiramate: MOA: Blocks Na+/Ca2+ channels, ↑GABA. ADRs: Paresthesia, cognitive slowing ('Dopamax'), weight loss, kidney stones. Teratogenic.
      • Valproic Acid: MOA: ↑GABA, blocks Na+/T-type Ca2+ channels. ADRs: Weight gain, tremor, hepatotoxicity. ⚠️ Highly teratogenic.

        ⭐ 📌 Valproic Acid: Highly teratogenic (neural tube defects) - Black Box Warning.

  • Injectable Prophylactics:
    • CGRP Monoclonal Antibodies: Erenumab (receptor), Fremanezumab, Galcanezumab (ligand). SC monthly/quarterly. ADRs: Injection site reactions, constipation (Erenumab).
    • OnabotulinumtoxinA: For chronic migraine (≥15 headache days/month). MOA: Inhibits CGRP release. Admin: 31 specific sites.
  • Other Options: Candesartan (ARB), Riboflavin (Vit B2), Coenzyme Q10, Magnesium.
  • Menstrual Migraine Prophylaxis: Frovatriptan, NSAIDs perimenstrually.

Migraine Management: Diagnosis, Treatment, Follow-up

High‑Yield Points - ⚡ Biggest Takeaways

  • Triptans (5-HT1B/1D agonists) are first-line for acute migraine attacks; contraindicated in CAD/PVD.
  • Ergotamine (non-selective 5-HT agonist) causes significant vasoconstriction and nausea; less preferred.
  • CGRP antagonists ("-gepants" for acute, "-mabs" for prophylaxis) are novel targeted therapies.
  • Prophylaxis mainstays: Propranolol, Amitriptyline, Topiramate, Valproate, CGRP mAbs.
  • Risk of Serotonin Syndrome with concurrent use of triptans/ergots and SSRIs/SNRIs.
  • Medication Overuse Headache (MOH) is a critical concern with frequent acute drug use (≥10-15 days/month).

Practice Questions: Migraine Therapeutics

Test your understanding with these related questions

A 35-year-old woman presents with a persistent, throbbing headache on one side of her head, associated with nausea and sensitivity to light. What is the most likely diagnosis?

1 of 5

Flashcards: Migraine Therapeutics

1/10

Drug of choice for acute severe migraine is

TAP TO REVEAL ANSWER

Drug of choice for acute severe migraine is

Triptans

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial